Massive Bio Scoops Up Additional $2.6M

USA –

NEW YORK, NY, Massive Bio, a leader in precision medicine and artificial intelligence (AI) enabled patient-centric clinical trial enrollment, has announced a $2.6 million round of funding.
The round was led by Revo Capital with additional participation from Cavendish Impact Foundation (CIF), through their donor advised fund at ImpactAssets. The investment brings Massive Bio's total funding since launch to $6.6 million and will enable the biotechnology company to scale to meet the demand in the U.S. and overseas for its oncology clinical trial recruitment platform solutions. The financing round builds on an exceptional year for Massive Bio which saw a rapidly growing roster of clients across the pharmaceutical company and contract research organization (CRO) industry globally, and exponential demand which was further accelerated by COVID-19.

Massive Bio's mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability. Massive Bio (https://massivebio.com/) is an Artificial Intelligence (AI)-driven platform connecting cancer patients and their community oncologists to bio-pharmaceutical clinical trials yielding profound improvement in access and match rates, leading to faster drug development timelines and creating novel oncology data ecosystem for improved protocol design and real-world insights. Massive Bio controls patient enrollment value chain starting patient identification, following with AI based virtual pre-screening outside the site and resolving last mile issues for clinical trial enrollment. While improving cancer patients' lives, Massive Bio serves close to two dozen pharmaceutical companies and contract research organizations (CROs) and providing patient recruitment, site selection and real-world data services in oncology. Massive Bio has been founded in 2015, headquartered in NYC and privately funded by strategic and financial investors.

Massive Bio

90 West St. #12M – New York, NY 10006

844-627-7246

https://massivebio.com/